Publication:

Teriparatide therapy in joint replacement surgery: mitigating complications and improving patient outcomes in osteoarthritis

Background Teriparatide, a synthetic form of parathyroid hormone, has gained significant recognition as an effective treatment for osteoporosis. Its ability to stimulate bone formation and improve bone mineral density has made it a valuable therapeutic option in managing this prevalent skeletal disorder. However, its safety and potential benefits in preventing bone mineral density (BMD) loss after joint replacement surgery and post-surgical complications have yet to be extensively investigated.

Methods This retrospective study included 32 patients who received teriparatide following joint replacement surgery for osteoarthritis. The analysis focused on assessing teriparatide’s effectiveness in any reductions in post-surgical complications and adverse events, if any.

Results No teriparatide-related adverse events and post-surgical complications were reported during the follow-ups and the entire study duration.

Conclusions Teriparatide demonstrated effectiveness in joint replacement patients. Further research is needed to explore long-term benefits and effects on implant longevity.